[ad_1] October 05, 2018 Belviq, a serotonin 2C receptor agonist, is approved for chronic weight management. According to new data from the CAMELLIA-TIMI 61 study, treatment with lorcaserine (Belviq; Eisai) was associated …
Read More »Lorcaserin reduces the risk of diabetes incidence in patients with prediabetes
